206 related articles for article (PubMed ID: 30296252)
21. [The clinical significance of expression and amplification of FGF3 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(36):2556-9. PubMed ID: 17198565
[TBL] [Abstract][Full Text] [Related]
22. [DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome].
Zhu JN; Wu KJ; Guan ZF; Liu LX; Ning ZY; Zhou JC; Wang XY; Fan JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):591-4. PubMed ID: 25286682
[TBL] [Abstract][Full Text] [Related]
23. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
24. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
25. Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.
Sami MM; Sherief MH; El-Abaseri TB; El-Sakka AI; El-Serafi AT
Urologia; 2023 May; 90(2):248-260. PubMed ID: 36670543
[TBL] [Abstract][Full Text] [Related]
26. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
27. Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint.
Bruyere F; Corcoran NM; Berdjis N; Namdarian B; Pedersen J; Ockrim J; Voelzke BB; Costello AJ; Hovens CM
BJU Int; 2008 Jul; 102(2):247-52. PubMed ID: 18341621
[TBL] [Abstract][Full Text] [Related]
28. Expression and prognostic significance of survivin in the progression of bladder transitional cell cancer.
Wang Y; Zhu Z; Zeng F; Wang L; Wu Y; Xia W; Xing S
J Huazhong Univ Sci Technolog Med Sci; 2007 Aug; 27(4):444-7. PubMed ID: 17828507
[TBL] [Abstract][Full Text] [Related]
29. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
32. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer.
Türkeri LN; Erton ML; Cevik I; Akdaş A
Urology; 1998 Apr; 51(4):645-9. PubMed ID: 9586623
[TBL] [Abstract][Full Text] [Related]
33. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
34. Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients.
Wang ZY; Zhang W; Yang JJ; Song DK; Wei JX; Gao S
Neoplasma; 2016; 63(6):991-998. PubMed ID: 27596300
[TBL] [Abstract][Full Text] [Related]
35. Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer.
Yao HQ; Peng Y; Zhong ZZ; He HX; Li ZH
Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):177-9. PubMed ID: 14965820
[TBL] [Abstract][Full Text] [Related]
36. [Tumors of the urinary system. Current and old problems].
Minner S; Sauter G
Pathologe; 2009 Dec; 30 Suppl 2():179-84. PubMed ID: 19960299
[TBL] [Abstract][Full Text] [Related]
37. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
38. HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy.
Moustakas G; Kampantais S; Nikolaidou A; Vakalopoulos I; Tzioufa V; Dimitriadis G
J Int Med Res; 2020 Jan; 48(1):300060519895847. PubMed ID: 31937176
[TBL] [Abstract][Full Text] [Related]
39. Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma.
Chow NH; Tzai TS; Lin SN; Chan SH; Tang MJ
Eur Urol; 1993; 24(1):140-3. PubMed ID: 8365434
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma].
Ruan J; Weng ZL
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):429-31. PubMed ID: 20819483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
